Tickborne SFTS Virus Vaccine Development

项目总结/摘要 严重发热伴血小板减少综合征（SFTS）是一种新出现的蜱传 由SFTS病毒（SFTSV）引起的传染病。SFTSV被列为最危险的病毒 这些病原体很可能在不久的将来引起广泛的流行。的发生率 SFTSV感染已持续增加至5，000多人，死亡率为 从12%到高达30%不等。SFTSV诱导特征性血小板减少症， 与病毒性出血热非常相似受感染的蜱是人类SFTSV的主要来源 感染特别是，最近这种蜱传播到美国12个州， 在远东以外地区爆发疫情健康人群中SFTSV的血清流行病学调查 不同年龄组的人之间没有显著差异，但临床诊断的SFTS患者 年龄大于50岁，表明年龄是SFTS发病率和死亡率的关键危险因素。 目前没有有效的疫苗可用于SFTSV。本提案的目的是 全面测试和比较了4株SFTSV的免疫原性和保护效力， 在年龄依赖性雪貂模型中针对致死性SFTSV感染特异性疫苗候选物。

Project Summary/Abstract Severe fever with thrombocytopenia syndrome (SFTS) is a newly emerging tick-borne infectious disease caused by SFTS virus (SFTSV). SFTSV is listed in the most dangerous viral pathogens by the WHO that most likely cause wide epidemics in the near future. The incidence of SFTSV infection has continuously increased up to more than 5,000 humans with a mortality rate ranging from 12% to as high as 30%. SFTSV induces a characteristic thrombocytopenia that is remarkably similar to viral hemorrhagic fevers. Infected ticks are the major source of human SFTSV infection. Particularly, the recent spread of this tick to over 12 states of USA increases the potential for outbreaks of the disease beyond the Far East Asia. The sero-prevalence of SFTSV in healthy people is not significantly different among age groups, but clinically diagnosed SFTS patients are older than ~50 years, suggesting that age is the critical risk factor for SFTS morbidity and mortality. No effective vaccines are currently available for SFTSV. The goal of this proposal is to comprehensively test and compare the immunogenicity and protection efficacy of four SFTSV- specific vaccine candidates against lethal SFTSV infection in age-dependent ferret model.